AP 12009 (Trabedersen)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AP 12009 (Trabedersen), covering 2019-02-15 to 2019-02-15. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 [Phase 1]